Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BFRINASDAQ:BIVIOTCMKTS:OASMYNASDAQ:OCUPNASDAQ:SNPX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$1.69+1.8%$1.39$0.61▼$13.42$8.60M0.83638,713 shs25,769 shsBIVIBioVie$0.49-3.9%$0.74$0.45▼$8.69$19.52M0.792.12 million shs775,654 shsOASMYVivesto$0.02$0.02$0.00▼$0.02$3.59M21.087 shsN/AOCUPOcuphire Pharma$1.54$2.08$1.50▼$6.60$37.96M0.33217,920 shs110,604 shsSNPXSynaptogenix$4.41-3.3%$4.79$3.53▼$47.00$4.81M1.3343,157 shs3,502 shs7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera+1.81%+1.20%+52.25%+11.92%-84.91%BIVIBioVie-3.26%+0.10%-7.95%-46.81%-93.03%OASMYVivesto0.00%0.00%0.00%0.00%-60.00%OCUPOcuphire Pharma+0.33%-8.08%-24.38%-43.57%-70.31%SNPXSynaptogenix-3.22%-5.30%-10.85%-11.56%-80.39%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRIBiofrontera1.8029 of 5 stars3.53.00.00.01.10.01.3BIVIBioVie1.822 of 5 stars3.35.00.00.02.40.00.0OASMYVivestoN/AN/AN/AN/AN/AN/AN/AN/AOCUPOcuphire Pharma1.4707 of 5 stars3.51.00.00.00.61.71.3SNPXSynaptogenixN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRIBiofrontera3.00Buy$18.00965.09% UpsideBIVIBioVie2.50Moderate Buy$8.001,536.33% UpsideOASMYVivestoN/AN/AN/AN/AOCUPOcuphire Pharma3.00Buy$19.001,137.79% UpsideSNPXSynaptogenixN/AN/AN/AN/ACurrent Analyst RatingsLatest BIVI, OASMY, BFRI, OCUP, and SNPX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2024OCUPOcuphire PharmaAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$24.00 ➝ $20.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRIBiofrontera$34.07M0.25N/AN/A$3.16 per share0.53BIVIBioVieN/AN/AN/AN/A$0.42 per shareN/AOASMYVivesto$100K35.87N/AN/A$0.18 per share0.11OCUPOcuphire Pharma$19.05M2.00N/AN/A$2.20 per share0.70SNPXSynaptogenixN/AN/AN/AN/A$25.27 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRIBiofrontera-$20.13M-$15.82N/AN/AN/A-59.09%-344.98%-72.85%5/10/2024 (Estimated)BIVIBioVie-$50.26M-$1.17N/A∞N/AN/A-332.18%-137.85%5/10/2024 (Estimated)OASMYVivesto-$35.35MN/A0.00∞N/AN/A-99.73%-91.27%N/AOCUPOcuphire Pharma-$9.99M-$0.48N/AN/AN/A-52.42%-22.30%-20.27%5/20/2024 (Estimated)SNPXSynaptogenix-$6.04M-$26.25N/A∞N/AN/A-22.50%-18.10%5/20/2024 (Estimated)Latest BIVI, OASMY, BFRI, OCUP, and SNPX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/15/2024Q4 2023BFRIBiofronteraN/A-$2.33-$2.33-$6.31N/A$10.60 million3/8/2024Q4 2023OCUPOcuphire Pharma-$0.07-$0.21-$0.14-$0.21$3.47 million$1.69 million2/12/2024Q2 2024BIVIBioVie-$0.32-$0.22+$0.10-$0.22N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRIBiofronteraN/AN/AN/AN/AN/ABIVIBioVieN/AN/AN/AN/AN/AOASMYVivestoN/AN/AN/AN/AN/AOCUPOcuphire PharmaN/AN/AN/AN/AN/ASNPXSynaptogenixN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRIBiofronteraN/A1.280.67BIVIBioVieN/A1.471.47OASMYVivesto0.014.654.65OCUPOcuphire PharmaN/A13.3513.35SNPXSynaptogenixN/A7.147.14OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRIBiofrontera10.08%BIVIBioVie4.59%OASMYVivestoN/AOCUPOcuphire Pharma14.97%SNPXSynaptogenix10.34%Insider OwnershipCompanyInsider OwnershipBFRIBiofrontera0.69%BIVIBioVie4.80%OASMYVivestoN/AOCUPOcuphire Pharma8.70%SNPXSynaptogenix4.33%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBFRIBiofrontera835.09 million5.05 millionNo DataBIVIBioVie1839.92 million38.01 millionOptionableOASMYVivesto14179.35 millionN/ANot OptionableOCUPOcuphire Pharma1424.81 million22.65 millionOptionableSNPXSynaptogenix51.09 million1.04 millionNot OptionableBIVI, OASMY, BFRI, OCUP, and SNPX HeadlinesSourceHeadlineSynaptogenix, Inc.: Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listingfinanznachrichten.de - April 24 at 5:25 PMSynaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listingprnewswire.com - April 24 at 9:15 AMSynaptogenix announces reverse stock split to regain Nasdaq complianceuk.investing.com - April 5 at 8:47 AMWhat's Going On With Synaptogenix (SNPX) Stock?msn.com - April 4 at 5:46 PMSynaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listingfinance.yahoo.com - April 3 at 9:57 AMU.S. shares higher at close of trade; Dow Jones Industrial Average up 1.18%msn.com - February 22 at 8:39 PMSynaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disordersfinance.yahoo.com - December 19 at 2:36 PMSynaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer'sfinance.yahoo.com - December 6 at 2:15 PMSynaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technologyfinance.yahoo.com - November 2 at 11:29 AMSynaptogenix Inc’s latest rating changes from various analystsknoxdaily.com - September 27 at 3:37 PMSynaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Diseasefinance.yahoo.com - September 26 at 12:59 PMBryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Studyfinance.yahoo.com - September 7 at 10:07 AMSynaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosisprnewswire.com - July 19 at 9:02 AMSNPX price target predicted to rise nearly $14.00 in 12 monthsknoxdaily.com - July 14 at 2:37 PMShort Volatility Alert: Synaptogenix Incbenzinga.com - July 14 at 2:37 PMSynaptogenix Shares Halted On Circuit Breaker To The Upside, Stock Now Up 59.1%benzinga.com - July 13 at 1:58 PMSynaptogenix Shares Rise 48% After Alzheimer's Drug Abstract Accepted at Conferencemarketwatch.com - July 13 at 1:58 PMSynaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neurosciencefinance.yahoo.com - July 13 at 1:58 PMSNPX - Synaptogenix, Inc.finance.yahoo.com - June 24 at 6:33 PMSynaptogenix Provides Corporate Update and Outlines Potential Business Opportunitiesfinance.yahoo.com - March 7 at 10:14 AMSNPX.Oreuters.com - February 27 at 12:25 AMPeering Into Synaptogenix's Recent Short Interestmsn.com - December 20 at 12:40 PMSynaptogenix crashes 69% as Phase 2 trial for Alzheimer’s candidate failsseekingalpha.com - December 16 at 1:26 PMSynaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Diseasefinance.yahoo.com - December 16 at 1:26 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBiofronteraNASDAQ:BFRIBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.BioVieNASDAQ:BIVIBioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.VivestoOTCMKTS:OASMYVivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.Ocuphire PharmaNASDAQ:OCUPOcuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.SynaptogenixNASDAQ:SNPXSynaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.